Abstract 92P
Background
The relative lymphocyte count (RLC) is a simple and widely available host-related biomarker. RLC is explored as a potential marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer (NSCLC). The objective of this study was to investigate the predictive value of RLC reduction for occurrence of serious immune-related adverse events (sirAEs) in patients with metastatic NSCLC, treated in the clinic of Medical oncology of Military Medical Academy in Sofia, Bulgaria.
Methods
The information was obtained retrospectively from the medical documentation of the pts with metastatic NSCLC, treated with immunotherapy (mono or in a combination with chemotherapy) in our institution in the period from m.05.2018 to m.05.2023. Descriptive statistical analysis was used. The RLC is measured at the onset of treatment and compared with the RLC at the time of diagnosis of irAEs. For the pts without irAEs the comparison is made between the initial RLC, normal or abnormal, and the occurrence of reduction in RLC during the course of treatment. As a reduction in RLC is defined as the drop of the lymphocyte count with more than 50% of the initial value if the lower RLC value is under 20% of the WBC.
Results
Thirty four pts with metastatic NSCLC were treated with immunotherapy (first, second or consecutive line) in our institution during the last 5 years. 3/34 (9%) were diagnosed with grade 1 or 2 irAEs, 5/34 (15%) with sirAEs (grade 3 to 5). In 4/5 (80%) of the cases with sirAEs we observed a reduction in RLC. 0/3 (0%) of the pts with grade 1 or 2 irAEs and 9/26 (35%) of the pts without immune-related toxicities met the criteria for RLC reduction. The pts with sirAEs had significantly higher RLC reduction rate than the pts with low grade or without immune-related toxicities. The χ2 statistic was 8.6595, leading to a p-value of 0.03745.
Conclusions
Our data suggest that RLC reduction is a strong predictive biomarker for sirAEs (p<0.05). The underlying pathophysiologic mechanism of this observation remains to be determined.
Editorial acknowledgement
N/A
Clinical trial identification
N/A
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Functional characterization of the novel long intergenic non-coding RNA-RFC4, a transcript regulating chromosomal instability in prostate cancer
Presenter: Rogelio Montiel Manríquez
Session: Cocktail & Poster Display session
Resources:
Abstract
52P - The concentration of mutated copies of driver genes in plasma closely mirrors the disease course in colorectal cancer, lung cancer, and melanoma patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
53P - Heterogeneous characteristics of KRAS mutation subtypes in surgically resected lung adenocarcinomas
Presenter: Kazuya Takamochi
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - ATRX-deficient IDH-wildtype adult high-grade gliomas display novel, clinically relevant genetic patterns by comprehensive genomic profiling
Presenter: Gábor Bedics
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - EGFR variant allele frequency (VAF) impacts on metastatic NSCLC patients outcome during first-line osimertinib
Presenter: Silvia Teresa Riva
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Clinical characteristics and outcomes in non-small cell lung cancer (NSCLC) with tumour and germline BRCA1/2 mutations
Presenter: Greydon Arthur
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - Molecular investigation using microarray-based comparative genomic hybridization in patients with myelodysplastic syndrome and normal karyotype
Presenter: Mohamed abd naceur AMMAR
Session: Cocktail & Poster Display session
Resources:
Abstract
59P - Unraveling methylation signatures in RAS/BRAF wild-type colorectal cancer patients to identify predictive biomarkers for anti-epidermal growth factor receptor therapy
Presenter: Ana Regina de Abreu
Session: Cocktail & Poster Display session
Resources:
Abstract
60P - Spindle cell sarcomas with tyrosine kinase rearrangement
Presenter: Lenka Krsková
Session: Cocktail & Poster Display session
Resources:
Abstract
61P - Deconvoluting the intra-tumour heterogeneity and subclonal evolution of CDK4/6 inhibitor resistance in ER+ breast cancer
Presenter: Ioanna Mavrommatis
Session: Cocktail & Poster Display session
Resources:
Abstract